| Trial ID: | L3397 |
| Source ID: | NCT04537624
|
| Associated Drug: |
Oral Semaglutide
|
| Title: |
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice
|
| Acronym: |
PIONEER REAL
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Oral Semaglutide
|
| Outcome Measures: |
Primary: Change in Glycated haemoglobin (HbA1c ), percent-points, From baseline (week 0) to End of Study visit (V3) (week 34-44) | Secondary: Relative change in body weight, percent, From baseline (week 0) to End of Study visit (V3) (week 34-44)|Absolute change in body weight, Kilogram (Kg), From baseline (week 0) to End of Study visit (V3) (week 34-44)|HbA1c <7% (Yes/No), Percentage of patients achieving or not achieving the target value, End of Study visit (V3) (week 34-44)|HbA1c reduction >=1%-points and body weight reduction of >=5% (Yes/No), Percentage of patients achieving or not achieving the reduction, From baseline (week 0) to End of Study visit (V3) (week 34-44)|HbA1c reduction >=1%-points and body weight reduction of >=3% (Yes/No), Percentage of patients achieving or not achieving the reduction, From baseline (week 0) to End of Study visit (V3) (week 34-44)
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
194
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2020-08-24
|
| Completion Date: |
2023-05-31
|
| Results First Posted: |
|
| Last Update Posted: |
2024-09-19
|
| Locations: |
Master Centre Switzerland, Zurich, Oerlikon, CH-8050, Switzerland
|
| URL: |
https://clinicaltrials.gov/show/NCT04537624
|
